OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
A recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves
Requirements and implementation activities stemming from a phased rollout of the Drug Supply Chain Security Act (DSCSA) will be coming to a close on Nov. 27, 2023, barring a last-minute reprieve from FDA. At times, it has seemed as if the final phase of the DSCSA may never come to fruition, given the interim milestone timeline delays and a decade-long runway. But now, the finish line is finally in view, with less than 18 months until the DSCSA legislation’s goal of having complete traceability of the US pharma market.
Recently, there has been an increasing focus on this hot topic, highlighting the importance of DSCSA and the significant confusion still present in the market. Many manufacturers cite the lack of clarity, formal education, and official resources as the key drivers for not having a serialization solution in place today. This may also be why the upcoming DSCSA timelines create such confusion and frenzy. Whether companies were hoping to see additional timeline delays from FDA or simply lost track of time during the pandemic-induced void of 2020–2021, the time to act is now for companies without a full serialization solution in place.
DSCSA stipulates that by November 2023, the US will have an electronic, interoperable system that will monitor the movement of prescription drugs from manufacturing to dispensation.1
What does this mean for manufacturers?
There’s still time to implement solutions before November 2023, but not much. How much time is needed depends on what strides have already been taken toward preparation. When considering the breadth of manufacturers impacted by the DSCSA requirements and the limited resources available to implement such software connectivity, what time is left is precious. As heightened awareness cascades throughout the market, the backlog of manufacturers waiting to implement with distributor partners and third-party logistics (3PL) solution providers continues to grow. This backlog is not likely to diminish between now and November 2023.
According to the distributor serialization teams engaged with for this article, if a product isn’t yet aggregated, the “oh no!” moment is here. For manufacturers with inventory that is aggregated and serialized but who haven’t yet launched a total serialization solution with their trading partners, there is agreement that they should aim to begin implementation activities no later than this summer.
Some manufacturers question if the sense of urgency to aggregate inventory and implement end-to-end serialization programs is real—or if, instead, the haste is fabricated by trading partners for their own benefit. Manufacturers need to understand that the deadline and urgency are real. Companies’ aversion to risk may soon be a contributing factor to action over inaction.
Recommended next steps for manufacturers
Pushing up deadlines
Key distributors are setting their own deadlines for manufacturers ahead of the DSCSA 2023 requirements—some inventory aggregation deadlines have been set as early as November 2022. This is to prevent bottlenecks in EPCIS data connectivity and obstacles to the FDA’s timeline. Additional distributors and trading partners will likely follow suit to mitigate procrastination impacts.
What level of enforcement will these distributors enact upon their deadlines? Will they require changes to returns policies as a result? That has yet to be seen. However, one thing is certain: trading partners do not want to be left holding onto unsaleable inventory after November 2023. They are leveraging their discretionary guidance granted by the FDA to protect themselves between now and then as best they can.
About the Author
Shannon Hybner is Director at Archbow Consulting.